BOSTON–(BUSINESS WIRE)–Spirita Oncology, LLC, has initiated a Phase 1 clinical trial of anti-cancer agent E6201 in patients with central nervous system metastases from BRAF- or MEK-mutated metastatic melanoma. The trial is being carried out at the University of Arizona Cancer Center with Hani Babiker, M.D., as Principal Investigator. There are approximately 47,000 new cases of metastatic melanoma in the U.S. each year, with approximately 10,000 deaths. More than 15,000 of these patients devel

Source link